Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00085943 · ClinicalTrials.gov registry record · Phase 3
KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 866
- Enrollment target
NCT00085943 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 866 participants.
The verdict
NCT00085943, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 866 participants
- Enrollment target
Study Summary
This study will compare the ability of fosamprenavir 700 mg with ritonavir 100 mg twice a day or lopinavir 400 mg with ritonavir 100 mg twice a day both combined with a fixed dose combination tablet of abacavir 600 mg and lamivudine 300 mg once a day to suppress virus levels of HIV to less than 400 copies/mL of blood. In addition we will study the safety and tolerability of these compounds over the 48 week study period in patients naive to anti-HIV therapy.
Interventions
- DRUG Ritonavir
- DRUG LEXIVA (GW433908)
- DRUG KALETRA
- DRUG EPIVIR
- DRUG Ziagen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 866 participants |
| Start Date | 2004-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00085943
The ClinicalTrials.gov registry entry for NCT00085943 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 866 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Ritonavir is the first listed.
NCT00085943 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00085943 about?
NCT00085943 is a clinical study titled "KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks". This study will compare the ability of fosamprenavir 700 mg with ritonavir 100 mg twice a day or lopinavir 400 mg with ritonavir 100 mg twice a day both combined with a fixed dose combination tablet of abacavir 600 mg and lamivudine 300 mg once a day to suppress virus levels of HIV to less than 400 ...
What is the current status of trial NCT00085943?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 866 participants. The study started on 2004-05.
What interventions are being tested in trial NCT00085943?
The interventions under investigation include: Ritonavir (DRUG), LEXIVA (GW433908) (DRUG), KALETRA (DRUG), EPIVIR (DRUG), Ziagen (DRUG).
Who is sponsoring clinical trial NCT00085943?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.